Profil
Clayton A.
Buck served as the Chief Executive Officer at The Wistar Institute from 1975 to 2004.
He also worked as a Director of Research and Development at Immune Control, Inc. and as a Professor at the University of Pennsylvania.
Buck received his undergraduate degree from Kansas State University and his doctorate from Montana State University.
Anciens postes connus de Clayton A. Buck
| Sociétés | Poste | Fin |
|---|---|---|
Immune Control, Inc.
 Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Directeur Technique/Scientifique/R&D | 06/12/2012 |
The Wistar Institute
 The Wistar Institute BiotechnologyHealth Technology The Wistar Institute provides biomedical research services. It researches on diseases such as cancer, cardiovascular, autoimmune disorders and infectious diseases and develops vaccine. The company was founded in 1892 and is headquartered in Philadelphia, PA | President | 01/12/2004 |
| University of Pennsylvania | Corporate Officer/Principal | - |
Formation de Clayton A. Buck
| Kansas State University | Undergraduate Degree |
| Montana State University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Immune Control, Inc.
Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Health Technology |
The Wistar Institute
The Wistar Institute BiotechnologyHealth Technology The Wistar Institute provides biomedical research services. It researches on diseases such as cancer, cardiovascular, autoimmune disorders and infectious diseases and develops vaccine. The company was founded in 1892 and is headquartered in Philadelphia, PA | Health Technology |
